Skip to main content
ATAI
NASDAQ Life Sciences

AtaiBeckley Secures Key Regulatory Clearances for Eli Lilly Acquisition

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
9
Price
$7.34
Mkt Cap
$2.722B
52W Low
$3.265
52W High
$7.45
52W Position info
125% above low
Off High info
1.5% below high
Rel. Volume info
0.4× avg
Market data snapshot near publication time

ATAI has more than doubled off its 52-week low of $3.265.

Summary

AtaiBeckley announced it has received key regulatory clearances for its acquisition by Eli Lilly, including the expiration of the U.S. HSR waiting period and positive feedback from UK and Australian antitrust reviews.


Key Events · M&A and Partnerships · ATAI

  • U.S. Antitrust Clearance

    The waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 expired on August 28, 2026, clearing a major hurdle for the acquisition.

  • UK Regulatory Review

    The UK Competition and Markets Authority (CMA) indicated on August 21, 2026, that it had no further questions regarding the merger.

  • Australian Regulatory Approval

    The Australian Competition and Consumer Commission (ACCC) determined on August 27, 2026, that the merger may be consummated, subject to a waiting period expiring on September 10, 2026.


Analysis · ATAI · Life Sciences

This filing provides crucial updates on the regulatory approvals for the previously announced acquisition by Eli Lilly. The expiration of the U.S. HSR waiting period and positive indications from UK and Australian authorities significantly de-risk the merger, moving it closer to completion. These clearances are essential milestones for the deal to close, reinforcing the likelihood of the acquisition proceeding as planned.

How filings like this one have moved

In the 30 days to Sep 10, 2026, 43.7% of the 583 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.52%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, ATAI was trading at $7.34 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.7B. The 52-week trading range was $3.27 to $7.45. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

ATAI - Latest Insights

ATAI
Sep 08, 2026, 5:09 PM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $7.32
Real-time Price: $7.30 info
Change: -$0.018 (-0.25%) info
Market Cap: $2.704B info
ATAI
Aug 31, 2026, 4:42 PM EDT
Source: Reuters
Importance Score:
7
Price at Filing: $7.34
Real-time Price: $7.30 info
Change: -$0.040 (-0.54%) info
Market Cap: $2.704B info
ATAI
Aug 11, 2026, 4:20 PM EDT
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $7.25
Real-time Price: $7.30 info
Change: +$0.050 (+0.69%) info
Market Cap: $2.704B info
ATAI
Aug 10, 2026, 6:09 AM EDT
Filing Type: DEFM14A
Importance Score:
9
Price at Filing: $7.24
Real-time Price: $7.30 info
Change: +$0.060 (+0.83%) info
Market Cap: $2.704B info
ATAI
Jul 29, 2026, 9:46 PM EDT
Filing Type: PREM14A
Importance Score:
9
Price at Filing: $7.17
Real-time Price: $7.30 info
Change: +$0.130 (+2%) info
Market Cap: $2.704B info